Evidence map›Paper›PMID 34547867›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2021

[The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].

Y Yang, Z J Xia, W H Zhang, C C Fu, L Bao, B Chen, K Y Ding, S L Wang, J Luo, B Z Li and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Y YangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Z J XiaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
W H ZhangDepartment of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.
C C FuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 210056, China.
L BaoDepartment of Hematology, Beijing Jishuitan Hospital, Beijing 100035, China.
B ChenDepartment of Hematology, The Affiliated Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, China.
K Y DingDepartment of Hematology, Anhui Provincial Cancer Hospital, Hefei 230031, China.
S L WangDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
J LuoDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
B Z LiDepartment of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
L M HuaDepartment of Hematology, The Affiliated Hospital of Hebei University, Baoding 071030, China.
W YangDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
X ZhouDepartment of Hematology, Wuxi People Hospital, Wuxi 214023, China.
L WangDepartment of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510280, China.
T H XuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
W D WangDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
G L WuDepartment of Hematology, Anhui Provincial Cancer Hospital, Hefei 230031, China.
Y HuangDepartment of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
J LiDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
P LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAgedAntineoplastic Combined Chemotherapy ProtocolsBoron CompoundsChinaDexamethasoneGlycineHumansLenalidomideBoron CompoundsDexamethasoneGlycineixazomibLenalidomideIxazomibLenalidomideMultiple myelomaSafetyTreatment outcome

Identifiers

PMID34547867
PMCPMC8501289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.